AZ-话题@MedSci

#AZ#

260篇内容 | 4200人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714848, encodeId=fb541e148483a, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=知名科研团队十年研发，港睿科技Raze蓝光宝清新上市, objectType=article, longId=181219, objectId=ef9e1812191e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef9e1812191e, replyNumber=0, likeNumber=44, createdTime=2020-06-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef9e1812191e, moduleTitle=知名科研团队十年研发，港睿科技Raze蓝光宝清新上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef9e1812191e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714835, encodeId=ec1a1e1483550, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=168695, objectId=da9416869531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9416869531, replyNumber=0, likeNumber=82, createdTime=2020-01-03, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9416869531, moduleTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9416869531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714850, encodeId=87271e148503f, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Clinigen计划在美国境外提供Azedra（I131）放射治疗嗜铬细胞瘤或神经节旁瘤, objectType=article, longId=181545, objectId=8f04181545db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f04181545db, replyNumber=0, likeNumber=80, createdTime=2020-05-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f04181545db, moduleTitle=Clinigen计划在美国境外提供Azedra（I131）放射治疗嗜铬细胞瘤或神经节旁瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f04181545db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714859, encodeId=65481e1485968, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：机械清创联合甲硝唑和阿莫西林全身用药是否可有效治疗种植体周围炎？, objectType=article, longId=188842, objectId=2b0a18884200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0a18884200, replyNumber=0, likeNumber=66, createdTime=2020-07-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0a18884200, moduleTitle=Braz Oral Res：机械清创联合甲硝唑和阿莫西林全身用药是否可有效治疗种植体周围炎？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0a18884200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714860, encodeId=24901e14860cd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Int Braz J Urol：早泄？试试补充点维生素D, objectType=article, longId=188893, objectId=dcd3188893a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcd3188893a7, replyNumber=0, likeNumber=77, createdTime=2020-08-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcd3188893a7, moduleTitle=Int Braz J Urol：早泄？试试补充点维生素D, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcd3188893a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714842, encodeId=74101e148426e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA授予AstraZeneca糖尿病药物达格列嗪治疗慢性肾病的快速指定, objectType=article, longId=178300, objectId=a66d1e83002b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d1e83002b, replyNumber=0, likeNumber=60, createdTime=2020-05-28, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d1e83002b, moduleTitle=FDA授予AstraZeneca糖尿病药物达格列嗪治疗慢性肾病的快速指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66d1e83002b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714833, encodeId=60291e1483352, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, objectType=article, longId=167750, objectId=63b216e750f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b216e750f8, replyNumber=0, likeNumber=74, createdTime=2020-02-20, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b216e750f8, moduleTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63b216e750f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714822, encodeId=87b31e148223e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力, objectType=article, longId=162181, objectId=976c162181d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976c162181d9, replyNumber=0, likeNumber=65, createdTime=2019-10-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976c162181d9, moduleTitle=Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976c162181d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714836, encodeId=fd8a1e148363a, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AJG： Pentazocine比双氯芬酸更适用于急性胰腺炎的镇痛, objectType=article, longId=168783, objectId=f23e168e83df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f23e168e83df, replyNumber=0, likeNumber=55, createdTime=2020-04-22, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f23e168e83df, moduleTitle=AJG： Pentazocine比双氯芬酸更适用于急性胰腺炎的镇痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f23e168e83df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714841, encodeId=83de1e14841f3, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Saroglitazar Magnesium治疗 PCOS患者非酒精性脂肪肝的临床试验已经开始, objectType=article, longId=178111, objectId=2e0c1e8111ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0c1e8111ba, replyNumber=0, likeNumber=95, createdTime=2019-10-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0c1e8111ba, moduleTitle=Saroglitazar Magnesium治疗 PCOS患者非酒精性脂肪肝的临床试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e0c1e8111ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714831, encodeId=7c041e148318f, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Cell Biol Int：研究发现AgNps通过激活RhoA-TAZ轴促进HPDLF的成骨分化, objectType=article, longId=166769, objectId=0eb9166e6998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eb9166e6998, replyNumber=0, likeNumber=107, createdTime=2019-10-20, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eb9166e6998, moduleTitle=Cell Biol Int：研究发现AgNps通过激活RhoA-TAZ轴促进HPDLF的成骨分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eb9166e6998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714853, encodeId=6d881e14853ba, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, objectType=article, longId=184532, objectId=4163184532b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4163184532b0, replyNumber=0, likeNumber=64, createdTime=2020-08-03, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4163184532b0, moduleTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4163184532b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成, objectType=article, longId=163025, objectId=cd3a16302581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd3a16302581, replyNumber=0, likeNumber=65, createdTime=2019-08-14, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd3a16302581, moduleTitle=J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd3a16302581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=加拿大卫生部批准大冢和灵北的REXULTI（brexpiprazole）作为重度抑郁症的辅助疗法, objectType=article, longId=160997, objectId=b4d916099e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4d916099e91, replyNumber=0, likeNumber=92, createdTime=2019-09-14, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4d916099e91, moduleTitle=加拿大卫生部批准大冢和灵北的REXULTI（brexpiprazole）作为重度抑郁症的辅助疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4d916099e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714852, encodeId=9b7a1e14852b6, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=中国NMPA批准Chipscreen Bioscience的Chidamide（Epidaza）用于乳腺癌, objectType=article, longId=183901, objectId=fc3c183901cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3c183901cb, replyNumber=0, likeNumber=81, createdTime=2020-06-20, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3c183901cb, moduleTitle=中国NMPA批准Chipscreen Bioscience的Chidamide（Epidaza）用于乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3c183901cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714845, encodeId=d4231e1484590, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC, objectType=article, longId=180842, objectId=a90e180842c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90e180842c3, replyNumber=0, likeNumber=73, createdTime=2020-05-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90e180842c3, moduleTitle=Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90e180842c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714818, encodeId=522f1e1481826, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=NEJM：每日1次Plazomicin治疗复杂性尿路感染疗效显著, objectType=article, longId=160699, objectId=88cd1606998d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88cd1606998d, replyNumber=0, likeNumber=81, createdTime=2019-05-21, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88cd1606998d, moduleTitle=NEJM：每日1次Plazomicin治疗复杂性尿路感染疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88cd1606998d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714815, encodeId=ff021e1481515, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：自我报告的根管治疗史是否可预测根尖炎的存在, objectType=article, longId=160085, objectId=30df16008566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30df16008566, replyNumber=0, likeNumber=73, createdTime=2020-01-30, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30df16008566, moduleTitle=Braz Oral Res：自我报告的根管治疗史是否可预测根尖炎的存在, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30df16008566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714824, encodeId=eaa51e148249f, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AP&T： Tegoprazan与埃索美拉唑治疗糜烂性食管炎患者中的疗效比较, objectType=article, longId=162304, objectId=0a08162304a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a08162304a5, replyNumber=0, likeNumber=53, createdTime=2019-07-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a08162304a5, moduleTitle=AP&T： Tegoprazan与埃索美拉唑治疗糜烂性食管炎患者中的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a08162304a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714821, encodeId=f7801e1482159, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, objectType=article, longId=161224, objectId=fd561612244e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd561612244e, replyNumber=0, likeNumber=75, createdTime=2019-10-21, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd561612244e, moduleTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd561612244e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

知名科研团队十年研发，港睿科技Raze蓝光宝清新上市

2020-06-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期

2020-01-03

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Clinigen计划在美国境外提供Azedra（I131）放射治疗嗜铬细胞瘤或神经节旁瘤

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：机械清创联合甲硝唑和阿莫西林全身用药是否可有效治疗种植体周围炎？

2020-07-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Int Braz J Urol：早泄？试试补充点维生素D

2020-08-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA授予AstraZeneca糖尿病药物达格列嗪治疗慢性肾病的快速指定

2020-05-28

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着

2020-02-20

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力

2019-10-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AJG： Pentazocine比双氯芬酸更适用于急性胰腺炎的镇痛

2020-04-22

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Saroglitazar Magnesium治疗 PCOS患者非酒精性脂肪肝的临床试验已经开始

2019-10-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Cell Biol Int：研究发现AgNps通过激活RhoA-TAZ轴促进HPDLF的成骨分化

2019-10-20

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究

2020-08-03

一叶知秋 (审核中...)

前往app查看评论内容

#AZ#

J Cell Mol Med：Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成

2019-08-14

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

加拿大卫生部批准大冢和灵北的REXULTI（brexpiprazole）作为重度抑郁症的辅助疗法

2019-09-14

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

中国NMPA批准Chipscreen Bioscience的Chidamide（Epidaza）用于乳腺癌

2020-06-20

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC

2020-05-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

NEJM：每日1次Plazomicin治疗复杂性尿路感染疗效显著

2019-05-21

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：自我报告的根管治疗史是否可预测根尖炎的存在

2020-01-30

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AP&T： Tegoprazan与埃索美拉唑治疗糜烂性食管炎患者中的疗效比较

2019-07-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功

2019-10-21

科室
- - 订阅+
  - 更多科室
工具
服务